唇裂和腭裂患者鼻窦疾病的流行病学评估及生活质量影响
这项前瞻性队列研究纳入90例≥12岁唇裂和/或腭裂患者,采用SNOT-22和NOSE量表评估鼻窦症状。患者鼻部阻塞症状评分显著高于SNOT-22评分,用药率超过诊断率,提示亚临床疾病负担较高,建议纳入患者报告结局指标以指导多学科管理。
要点
- 唇裂和/或腭裂患者存在有临床意义的鼻窦症状,以鼻部阻塞为主。
- 鼻窦药物使用率(36.7%)高于慢性鼻窦炎(12.2%)和过敏性鼻炎(21.1%)诊断率。
- SNOT-22总分在不同Veau分类间及与年龄间均无显著差异。
核心结论
- 唇裂和/或腭裂患者经历有临床意义的鼻窦症状,以鼻部阻塞为主。
- 药物使用超过鼻窦诊断,提示亚临床疾病患病率较高。
- 纳入患者报告结局指标对于揭示鼻窦疾病负担和指导多学科管理至关重要。
研究设计与样本
- 前瞻性队列研究,纳入2024年5月至2025年2月期间在一家三级颅面中心就诊的≥12岁有唇裂和/或腭裂病史的患者。
- 共纳入90例患者,大多数(83.3%)为非综合征性唇裂和/或腭裂。
- 参与者完成SNOT-22和NOSE量表,通过病历回顾收集临床和人口学数据。
主要发现
- 慢性鼻窦炎和过敏性鼻炎的报告率分别为12.2%和21.1%。
- 当前鼻窦药物使用率为36.7%。
- 因鼻窦症状转诊耳鼻咽喉科的比例仅为21.1%。
- NOSE评分显著高于SNOT-22评分(t = -3.65,p < 0.001)。
- 排除SNOT-22中的鼻部阻塞条目及两量表的生活质量条目后,NOSE评分仍显著更高(t = -4.65,p < 0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize the prevalence, clinical manifestations, and risk factors of sinonasal pathology in patients with cleft lip and/or palate (CL/P). METHODS: This prospective cohort study included patients aged ≥ 12 years with a history of CL/P, seen at a tertiary craniofacial center from May 2024 to February 2025. Participants completed the Sino-Nasal Outcome Test-22 (SNOT-22) and the Nasal Obstruction Symptom Evaluation (NOSE), assessing sinonasal symptoms. Clinical and demographic data were collected via chart review. Primary outcomes were normalized SNOT-22 and NOSE scores. Statistical analyses included paired and independent t-tests, Pearson correlation, and linear regression to evaluate associations with scores, Veau classification, and age. RESULTS: Ninety patients were included. Most (83.3%) had non-syndromic CL/P. Chronic rhinosinusitis and allergic rhinitis were reported by 12.2% and 21.1% of participants, respectively. Despite these rates, current sinonasal medication use was high (36.7%). Otolaryngology referrals for sinonasal symptoms were documented in only 21.1% of cases. NOSE scores were significantly higher than SNOT-22 scores (t = -3.65, p < 0.001). After excluding nasal obstruction items in SNOT-22, and quality of life items from both surveys, NOSE scores remained significantly higher (t = -4.65, p < 0.001). No significant differences in total SNOT-22 scores were found across Veau classifications (p = 0.406) or with age (Pearson's r = 0.123, p = 0.250). CONCLUSIONS: Patients with CL/P experience clinically meaningful sinonasal symptoms, predominantly nasal obstruction. Medication use exceeded sinonasal diagnoses, suggesting a higher prevalence of subclinical disease. Incorporating patient-reported outcome measures is essential to uncover the burden of sinonasal pathology and guide multidisciplinary management. LEVEL OF EVIDENCE: II.
引用
- Longfellow GA, Quinonez Del Cid E, Cook L, et al. Epidemiologic Assessment and Quality of Life Impact of Sinonasal Disease in Cleft Lip and Palate. Laryngoscope. 2025. PMID: 40751513. doi:10.1002/lary.70002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。